title: The intuitive case for β-blockers in patients with ESRD.
abstract: Sudden cardiac death (SCD) is common in dialysis patients accounting for up to 25% of all-cause mortality. Unlike in the general population, occlusive coronary artery disease is implicated in a minority of these deaths. Activation of the sympathetic nervous system is prevalent in the dialysis population and may underlie this high rate of SCD. β-blockers reduce SCD in the general population and, given their mode of action, β-blockers would seem to be an ideal class of agents to prevent SCD in dialysis patients. In this review, we will explore the etiology of SCD in dialysis patients and discuss the evidence supporting the use of β-blockers in patients with ESRD. We will also examine potential impediments to the use β-blocker in the dialysis population and outline directions for future trials in this area.
authors.forename: Rory F
authors.initials: RF
authors.lastname: McQuillan
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Chan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002423:Cause of Death / Q000639:trends; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality / Q000628:therapy; D009864:Ontario / Q000453:epidemiology; D006435:Renal Dialysis; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists